美股市场个股详情

SUPN Supernus Pharmaceuticals

添加自选

30.420
-0.410-1.33%

收盘价 05/06 16:00 (美东)

30.420
0.0000.00%

盘后 16:09 (美东)

16.72亿总市值1521.00市盈率TTM

Supernus Pharmaceuticals股票讨论区

登录发表评论

Moomoo AI

01/26 20:21

Supernus Pharmaceuticals' high P/E ratio is sustained by expectations of robust future growth, surpassing market average. Investors' belief in insignificant earnings deterioration risk bolsters the share price.

The Price Is Right For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Moomoo AI

2023/11/04 00:16

Caution is raised with substantial selling of Supernus Pharmaceuticals stock by key insiders and lack of buying in the past year. Insider ownership isn't high, indicating alignment with other shareholders. Evaluate carefully before purchasing due to these factors.

Supernus Pharmaceuticals Repeat Insider Selling Not A Positive Indicator

逍遥投资派

2023/05/26 23:15

$Supernus Pharmaceuticals(SUPN.US)$5年来营收除2019年外增长了4年，平均增速17%，营业利润反而在增长3年后，2021年大幅下滑54.7%，2022年继续大幅下滑42.6%，主要是由营业费用暴增引起的。
查了一下资产负债表，果然2021年商誉从4.42亿增加到9.02亿，这次收购使公司的运营效率大幅下滑，至今未缓过来。
2023Q1营收增长0.8%，营业利润在非常低的基数上增长了34%达到353万，净利润则由于利息收入的大幅下滑而萎缩了34%。
目前市盈率32.2，市盈率TTM 37.2，在运营效率改善前缺乏投资价值。

Bertramie

2021/10/12 15:33

$Supernus Pharmaceuticals(SUPN.US)$
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度